INFLAMOSTAT
Dead / Abandoned — Abandoned — no statement of use filed (as of 30 Mar 2026)
What this means for you
This application is over — abandoned 30 Mar 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98436739
- Mark type
- Stylized text
- Filed
- 06 Mar 2024
- Published for opposition
- 31 Dec 2024
- Abandoned
- 30 Mar 2026
- Attorney of record
- Constance B. Stefanou
Goods and services
- Class 003 — Cosmetics and cleaning preparations: Cosmetics; ingredient complex composed of synthetic and collagen peptides sold as an integral component of cosmetic preparations;
- Class 005 — Pharmaceuticals: Synthetic and collagen peptides for use in the fields of medical diagnostics and biotechnology, namely, for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; pharmaceutical preparations for use in the fields of medical diagnostics and biotechnology, namely, topical drugs for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides for pharmaceutical purposes for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides for the treatment of various conditions and diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides sold as ingredient in pharmaceutical preparations for the treatment immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; pharmaceutical preparations containing synthetic and collagen peptides for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; chemical preparations for sanitary use, namely, for coating medical devices, and for wound dressings; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; injectable pharmaceuticals for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases;
Owner
- 3Helix Inc., Salt Lake City, UT, US
- 3Helix Inc., Salt Lake City, UT, US
Prosecution history
- 30 Mar 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 30 Mar 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 27 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Mar 2025 — SOU EXTENSION 1 GRANTED
- 27 Mar 2025 — SOU EXTENSION 1 FILED
- 27 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 31 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 Dec 2024 — PUBLISHED FOR OPPOSITION
- 25 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Dec 2024 — EXAMINER'S AMENDMENT ENTERED
- 09 Dec 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 09 Dec 2024 — EXAMINERS AMENDMENT E-MAILED
- 09 Dec 2024 — EXAMINERS AMENDMENT -WRITTEN